Immune drug trial aims to zap precancerous cervical cells
NCT ID NCT04712851
Summary
This study is testing if a drug called pembrolizumab can help the body's immune system clear high-grade abnormal cervical cells (CIN 2/3) before they turn into cancer. It will involve about 25 women who will receive the drug through an IV every six weeks for about six months. The main goal is to see if the treatment can completely eliminate the abnormal cells, potentially offering a non-surgical option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California at Los Angeles / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.